Can Natural Gas Help Intrexon Take the Lead in Isobutanol Development?
Maxx Chatsko, The Motley Fool - Motley Fool - Thu Apr 17, 10:00AM CDT
Synthetic biology company Intrexon has been busy lately. In the last six months the company has entered into and expanded several exclusive channel collaborations, or ECCs, for numerous health care applications and completed the acquisition of...
Intrexon Appoints Former Ernst & Young CEO James S. Turley to Board of Directors
PR Newswire - Wed Apr 16, 2:17PM CDT
Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the appointment of James S. Turley to its Board of Directors, effective April 16. Mr. Turley will occupy the board seat vacated by Thomas Reed, Ph.D., Founder and Chief Science Officer of Intrexon. Dr. Reed will continue to serve as Chief Science Officer.
ZIOPHARM Presents Preclinical Data at AACR Annual Meeting Supporting Controlled DNA-based IL-12 Therapy for Brain Cancer
GlobeNewswire - Tue Apr 08, 11:51AM CDT
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today the presentation of data from a study demonstrating the anti-tumor effects and tolerability of Ad-RTS-mIL-12 in a glioblastoma (brain cancer) murine model. Ad-RTS-IL-12 is a novel DNA-based therapeutic candidate for the controlled, local expression of IL-12, an important protein for stimulating an anti-cancer T cell immune response.
Soligenix Announces $200,000 NIDCR SBIR Grant Award Supporting Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer
PR Newswire - Mon Apr 07, 6:15AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Dental and Craniofacial Research (NIDCR) has awarded Soligenix a Small Business Innovation Research (SBIR) grant to support the conduct of its Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.
ZIOPHARM Upgraded to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 4:50PM CDT
ZIOPHARM's track record is pretty impressive with the company delivering positive surprises in the last couple of quarters.
5 Stocks Insiders Love Right Now
at The Street - Wed Apr 02, 11:13AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
AmpliPhi to Present at 13th Annual Needham Healthcare Conference
Business Wire - Tue Apr 01, 7:01AM CDT
AmpliPhi BioSciences Corporation. (OTCBB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that Philip Young, President and CEO, will be presenting a corporate overview at the 13th Annual Needham Healthcare Conference on Tuesday, April 08 at 8:40am EDT at the Westin NY Grand Central Hotel in New York, NY.
Pending Applications, Closed Public Offering, Joint Venture Formation, Executive Appointment, and Commercial Launch - Analyst Notes on Gilead, Enzymotec, Intrexon, Advaxis, and Repligen
PR Newswire - Tue Apr 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Enzymotec Ltd. (NASDAQ: ENZY), Intrexon Corporation (NYSE: XON), Advaxis, Inc. (NASDAQ: ADXS), and Repligen Corporation (NASDAQ: RGEN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Intrexon Announces Annual Report and Fourth Quarter Financial Results
PR Newswire - Mon Mar 31, 3:30PM CDT
Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced its 2013 annual and fourth quarter results for 2013.
Critical Alerts For Citigroup, Visa, Intrexon, Red Hat, and Electronic Arts Released By InvestorsObserver
PR Newswire - Mon Mar 31, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for C, V, XON, RHT, and EA.
Synthetic Biologics Reports Year End 2013 Financial Results and Operational Update
PR Newswire - Mon Mar 31, 6:00AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, today reported financial results for the year ended December 31, 2013 and provided operational highlights.
Intrexon to increase gas-to-liquid bioconversion through its newly formed joint venture
M2 - Fri Mar 28, 4:50AM CDT
Synthetic biology company Intrexon (NYSE:XON) revealed on Thursday the establishment of a joint venture to optimise and scale-up its gas-to-liquid (GTL) bioconversion platform for the production of fuels and lubricants.
Intrexon Forms Energy Collaboration for Gas-to-Liquids Bioconversion
PR Newswire - Thu Mar 27, 12:44PM CDT
Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the formation of Intrexon Energy Partners (IEP), a joint venture with a select group of external investors, to optimize and scale-up Intrexon's gas-to-liquid (GTL) bioconversion platform for the production of fuels and lubricants. IEP's first target product is isobutanol for gasoline blending.
Soligenix Reports Year-End 2013 Financial Results and Highlights Recent Accomplishments
PR Newswire - Wed Mar 26, 6:15AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the year ended December 31, 2013.
Fibrocell Science to Present at 2nd Annual Regen Med Investor Day and BioCentury Future Leaders in the Biotech Industry Conference
Business Wire - Thu Mar 20, 4:30PM CDT
Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that Gregory Weaver, senior vice president and chief financial officer of Fibrocell Science, will present at the Alliance for Regenerative Medicine's (ARM) 2nd Annual Regen Med Investor Day at 4:00 p.m. EDT on Wednesday, March 26, 2014 at the Metropolitan Club in New York, and the BioCentury Future Leaders in the Biotech Industry conference at 10:30 a.m. EDT on Friday, March 28, 2014 at the Millennium Broadway Hotel & Conference Center in New York. Mr. Weaver will discuss the company's autologous fibroblast technology, its therapeutic candidates in development, and its collaboration with Intrexon Corporation (NYSE: XON) to develop genetically-modified personalized biologics.
Why Sinovac Biotech, Burlington Stores, and ZIOPHARM Oncology Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 20, 4:15PM CDT
Mixed, but stabilizing, economic data was the name of the game today that helped push the broad-based S&P 500 higher, practically erasing almost all of yesterday's losses. As per the norm, we got initial weekly jobless claims data today,...
Intrexon Deal Update Overshadows Q4 Loss at Fibrocell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 9:00AM CDT
Fibrocell's deal with Intrexon holds great promise.
Vista Partners Initiates Coverage on Soligenix, Inc. (Ticker: SNGX); $5.50 Price Target
Marketwire - Tue Mar 18, 8:02AM CDT
Vista Partners announced today that it has initiated coverage on Soligenix, Inc. (OTCBB: SNGX) with a twelve-month price target of $5.50. Soligenix, Inc. is a New Jersey based clinical stage biopharmaceutical company committed to developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases. Ross Silver, Principal Analyst at Vista Partners, stated, "Soligenix has signed an exclusive worldwide collaboration deal with Intrexon Corporation ($2.9B mkt cap) (NYSE: XON) to develop a novel passive immunotherapy for Melioidosis. Melioidosis, also known as Bp, is an often deadly infectious disease caused by the bacterium, Burkholderia pseudomallei, with some symptoms similar to those of the flu and pneumonia. Melioidosis occurs in many different places around the globe, currently however it is of greatest concern in southeast-Asia and northern Australia, where public officials see it as a major threat to the health of the population." Mr. Silver continues, "The Company also has an exclusive commercial collaboration with SciClone Pharmaceuticals ($250M mkt cap) (NASDAQ: SCLN) in China for SGX942 in the treatment of oral mucositis." Mr. Silver concludes, "The Company boasts a diverse pipeline with nine prospective drug candidates. The science behind the Company's prospective therapies has been and continues to be validated by a number of significant, important and influential entities such as government organizations and major pharmaceutical companies. To date the Company has been awarded approximately $40M mainly through BARDA, NIH and FDA grants/contracts. The Company has up to approximately $34 million in active government contract and grant funding still available to support its associated research programs through 2018."
Initiation of Clinical Trials, Completed Acquisitions, Financial Results, and Earnings Release Schedules - Analyst Notes on Cell Therapeutics, Intrexon, Chimerix, Receptos, and Revance Therapeutics
PR Newswire - Tue Mar 18, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Cell Therapeutics, Inc. (NASDAQ: CTIC), Intrexon Corporation (NYSE: XON), Chimerix, Inc. (NASDAQ: CMRX), Receptos, Inc. (NASDAQ: RCPT), andRevance Therapeutics, Inc. (NASDAQ: RVNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register